Skip to content

Trial Summary

daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC)



ACTRN/NCT /ethics:


Scientific title:

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3)

Sponsor / Cooperative group:

Novartis Pharmaceuticals

Trial & Patient Characteristics

Cancer TypeBowel and colon
Trial TypeTreatment
PhasePhase II
Age Range-
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2021-11-15
Anticipated End Date2025-02-17

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead
Phone08 8359 2565
Principal InvestigatorA/Prof Rohit Joshi
Recruitment StatusRecruiting